Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reframing the evaluation of integrated care; examples from the NHS in England.

Health policy (Amsterdam, Netherlands)·2025
Same author

Transferability of Lessons From Program Evaluations: Iron Laws, Hiding Hands and the Evidence Ecosystem.

Evaluation review·2024
Same author

COVID-19 Genomics UK (COG-UK) Consortium: Final Report.

Rand health quarterly·2022
Same author

Integrated Care in England - what can we Learn from a Decade of National Pilot Programmes?

International journal of integrated care·2021
Same author

Innovation as a Driver of Quality and Productivity in UK Healthcare: Creating and Connecting Receptive Places-Emerging Insights.

Rand health quarterly·2018
Same author

Transforming Urgent and Emergency Care and the Vanguard Initiative: Learning from Evaluation of the Southern Cluster.

Rand health quarterly·2018

Related Experiment Videos

Pharmacogenetics and uncertainty: implications for policy makers.

Tom Ling1, Ann Raven

  • 1Anglia Ruskin University, Cambridge, East Road, Cambridge CB1 1PT, UK. tling@rand.org

Studies in History and Philosophy of Biological and Biomedical Sciences
|September 19, 2006
PubMed
Summary

Policy makers face pressure to decide on pharmacogenetics, a field with potential benefits and risks. This paper maps uncertainties and suggests strategies for navigating complex decisions in this emerging scientific area.

Related Experiment Videos

Area of Science:

  • Pharmacogenetics
  • Health Policy
  • Decision Science

Background:

  • Policy makers increasingly face pressure to make decisions under uncertainty.
  • New scientific developments like pharmacogenetics present both significant benefits and risks.
  • Extensive but unclear evidence complicates decision-making processes.

Purpose of the Study:

  • To map the uncertainties surrounding pharmacogenetics development and implementation.
  • To explore the interests that could be served by pharmacogenetics.
  • To provide suggestions for policy makers to manage tensions and dilemmas.

Main Methods:

  • Mapping of uncertainties in pharmacogenetics policy.
  • Drawing on principles of deliberative democracy.
  • Utilizing futures thinking methodologies.

Main Results:

  • Identified uncertainties in the context and interests related to pharmacogenetics.
  • Highlighted the UK's potential leadership role and benefits from pharmacogenetics.
  • Recognized the threat of uncertainties overwhelming policy makers' capacity to act.

Conclusions:

  • Policy makers can manage pharmacogenetics-related tensions by moving towards a more stable policy arena.
  • Suggestions are provided based on deliberative democracy and futures thinking.
  • Effective management of uncertainty is crucial for realizing pharmacogenetics benefits.